Abstract Details

Title No Olfactory Deficit in Episodic Cluster Headache

Topic Headache

Presentation(s) P01 - (-)

Poster/Presentation
Number 075

Objective

Background Cluster headache (CH) is a rare primary headache disorder, which is characterized by strictly unilateral severe headache attacks. Its pathophysiology is still obscure. Electrophysiological findings in episodic CH showed an asymmetric facilitation of trigeminal nociceptive processing which is predominantly located on brainstem level even in remission periods. But as in other headache syndromes, such as migraine, alterations and disregulation in other senses are in discussion. A diffusion tensor imaging study detected frontobasal alterations and the authors suggested an involvement of the olfactory system(Teepker et al.). Furthermore preliminarily data from a small study using olfactory testing even suggested alterations in olfactory performance and raised the question of clinical implications of this finding.

Design/Methods We investigated 30 patients(mean age: 46y; m:f = 24:6) suffering episodic cluster headache and currently being in a remission periods, using the commercially available 'Sniffin'Sticks' test battery testing nasal chemosensory performance. With this system based on pen-like odor dispensing devices olfactory performance was tested regarding odor threshold, odor discrimination, odor identification. Determined scores were then compared to the standardized reference values previously defined in a big control cohort.

Results Neither in overall olfactory performance (TDI-Value), calculated as the sum of the subscores, nor in any of those, we were able to detect alterations in olfactory performance. TDI Value(ref.: 30.5) was 31.39±5.49 ipsilateral and 30.47±4.76 contralateral to headache. Scores for threshold, discrimination and identification behaved comparable and will be presented as table.

Conclusions No lack of olfactory performance was observed in the patient cohort regarding odor threshold, discrimination, identification or TDI-overall performance. Furthermore no lateralization in nasal chemosensory performance could be identified in side comparison in all domains. This is in contrast to previous findings and pulls CH apart from being a multisensory disorder.

Authors/Disclosures
Steffen Naegel, MD (Alfried Krupp Krankenhaus) PRESENTER	No disclosure on file
Mona Stecker (Winthrop University Hospital)	No disclosure on file
	No disclosure on file
Dagny N. Holle, MD	Dr. Holle has nothing to disclose.
	No disclosure on file
Susanne Knake	No disclosure on file
H. C. Diener, MD, FAAN (University Duisburg-Essen)	Dr. Diener has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Diener has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. Dr. Diener has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lundbeck. Dr. Diener has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. Dr. Diener has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Thieme. The institution of Dr. Diener has received research support from German Research Council.
	No disclosure on file
Zaza Katsarava, MD	Zaza Katsarava, MD has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allergan. Zaza Katsarava, MD has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Zaza Katsarava, MD has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Zaza Katsarava, MD has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TEVA. Zaza Katsarava, MD has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lilly. Zaza Katsarava, MD has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Zaza Katsarava, MD has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis.
Mark Obermann, MD, FAAN (Department of Neurology, Klinikum Weser-Egge)	No disclosure on file

��ɫ��

��ɫ��